These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

206 related items for PubMed ID: 17551678

  • 1. The treatment of polycythaemia vera: an update in the JAK2 era.
    Finazzi G, Barbui T.
    Intern Emerg Med; 2007 Mar; 2(1):13-8. PubMed ID: 17551678
    [Abstract] [Full Text] [Related]

  • 2. Risk-adapted therapy in essential thrombocythemia and polycythemia vera.
    Finazzi G, Barbui T.
    Blood Rev; 2005 Sep; 19(5):243-52. PubMed ID: 15963833
    [Abstract] [Full Text] [Related]

  • 3. Risk stratification, staging, and treatment of patients with polycythemia vera: Italian and European collaboration on low-dose aspirin in polycythemia data.
    Finazzi G.
    Semin Thromb Hemost; 2006 Apr; 32(3):276-82. PubMed ID: 16673282
    [Abstract] [Full Text] [Related]

  • 4. How I treat patients with polycythemia vera.
    Finazzi G, Barbui T.
    Blood; 2007 Jun 15; 109(12):5104-11. PubMed ID: 17264301
    [Abstract] [Full Text] [Related]

  • 5. Expertise-based management in essential thrombocythemia and polycythemia vera.
    Finazzi G, Barbui T.
    Cancer J; 2007 Jun 15; 13(6):372-6. PubMed ID: 18032974
    [Abstract] [Full Text] [Related]

  • 6. Polycythemia vera.
    Landolfi R, Nicolazzi MA, Porfidia A, Di Gennaro L.
    Intern Emerg Med; 2010 Oct 15; 5(5):375-84. PubMed ID: 20237866
    [Abstract] [Full Text] [Related]

  • 7. Evidence and expertise in the management of polycythemia vera and essential thrombocythemia.
    Finazzi G, Barbui T.
    Leukemia; 2008 Aug 15; 22(8):1494-502. PubMed ID: 18596737
    [Abstract] [Full Text] [Related]

  • 8. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
    Bellucci S, Michiels JJ.
    Semin Thromb Hemost; 2006 Jun 15; 32(4 Pt 2):381-98. PubMed ID: 16810614
    [Abstract] [Full Text] [Related]

  • 9. Therapy for polycythemia vera and essential thrombocythemia is driven by the cardiovascular risk.
    Barbui T, Finazzi G.
    Semin Thromb Hemost; 2007 Jun 15; 33(4):321-9. PubMed ID: 17525889
    [Abstract] [Full Text] [Related]

  • 10. [Diagnosis and therapy of polycythemia vera in the era of JAK2].
    Lengfelder E.
    Dtsch Med Wochenschr; 2013 Feb 15; 138(7):331-6. PubMed ID: 23393003
    [Abstract] [Full Text] [Related]

  • 11. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.
    Tefferi A.
    Am J Hematol; 2012 Mar 15; 87(3):285-93. PubMed ID: 22331582
    [Abstract] [Full Text] [Related]

  • 12. New Therapeutic Approaches in Polycythemia Vera.
    Falchi L, Newberry KJ, Verstovsek S.
    Clin Lymphoma Myeloma Leuk; 2015 Jun 15; 15 Suppl(0):S27-33. PubMed ID: 26297275
    [Abstract] [Full Text] [Related]

  • 13. [CME: Polycythemia vera].
    Wellauer Atencio M, Goede JS.
    Praxis (Bern 1994); 2019 Sep 15; 108(13):835-842. PubMed ID: 31571535
    [Abstract] [Full Text] [Related]

  • 14. Polycythemia Vera: An Appraisal of the Biology and Management 10 Years After the Discovery of JAK2 V617F.
    Stein BL, Oh ST, Berenzon D, Hobbs GS, Kremyanskaya M, Rampal RK, Abboud CN, Adler K, Heaney ML, Jabbour EJ, Komrokji RS, Moliterno AR, Ritchie EK, Rice L, Mascarenhas J, Hoffman R.
    J Clin Oncol; 2015 Nov 20; 33(33):3953-60. PubMed ID: 26324368
    [Abstract] [Full Text] [Related]

  • 15. [Recent advances in polycythemia vera treatment].
    Edahiro Y.
    Rinsho Ketsueki; 2020 Nov 20; 61(9):1187-1194. PubMed ID: 33162515
    [Abstract] [Full Text] [Related]

  • 16. Diagnosis and therapy of polycythemia vera.
    Lengfelder E, Merx K, Hehlmann R.
    Semin Thromb Hemost; 2006 Apr 20; 32(3):267-75. PubMed ID: 16673281
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. [Acquired mutation of JAK2 tyrosine kinase and polycythaemia vera].
    Pargade V, Darnige L, Gaussem P.
    Ann Biol Clin (Paris); 2006 Apr 20; 64(1):3-9. PubMed ID: 16420986
    [Abstract] [Full Text] [Related]

  • 20. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study.
    Campbell PJ, Scott LM, Buck G, Wheatley K, East CL, Marsden JT, Duffy A, Boyd EM, Bench AJ, Scott MA, Vassiliou GS, Milligan DW, Smith SR, Erber WN, Bareford D, Wilkins BS, Reilly JT, Harrison CN, Green AR, United Kingdom Myeloproliferative Disorders Study Group, Medical Research Council Adult Leukaemia Working Party, Australasian Leukaemia and Lymphoma Group.
    Lancet; 2005 Dec 03; 366(9501):1945-53. PubMed ID: 16325696
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.